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Purpose: To provide a systematic review with meta-analysis
for addressing the relationship between fecal bile acids (FBAs)
and colorectal cancer. Materials and Methods: Electronic
databases were searched for all observational studies that
examined the relationship between FBAs and colorectal cancer
or adenoma, and calculated weighted mean difference (WMD)
and 95% confidence interval (CI). Publication bias was
assessed with funnel plot. Results: Twenty case-control or
cohort studies were identified. All studies were pooled to
assess the relationship between total FBAs and cancer/adenoma
of the large bowel, however, no association was seen (WMD
0.61mg/g freeze-dried feces; 95% CI: -0.35-1.57). Significantly
increased concentration of chenodeoxycholic acid (CDCA)
was seen while pooling to assess the relationship between
CDCA and cancer/adenoma of the large bowel (WMD 0.13
mg/g freeze-dried feces; 95% CI: 0.01 - 0.25), especially for
colorectal cancer (WMD 0.28 mg/g freeze-dried feces; 95%
CI: 0.10 - 0.46). However, no significant differences in
deoxycholic acid (DCA), lithocholic acid (LCA), and primary
and secondary bile acids, were seen between patients with
cancer and patients with matched controls regardless of fixed
and random effects models. Conclusion: CDCA might play a
role in the etiology of colorectal cancer.
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INTRODUCTION
Epidemiological and experimental studies both
in vivo and in vitro suggest that fecal bile acids
(FBAs) may play a role in the etiology of
colorectal cancer.
1-4 It has previously been shown
by Hill et al,
1 in England and Reddy and Wynder
5
in the United States that the mean concentration
of total FBAs in patients with colon cancer were
higher than those in control subjects, however,
further studies failed to demonstrate similar
results, raising some doubts over the proposed
implication of bile acids.
6,7
Large bowel carcinogenesis is a multistage
process involving the formation and growth of the
adenoma, development of increasingly severe
epithelial dysplasia, and finally the progression to
malignancy; this process is referred to as the
adenoma-carcinoma sequence.
8 In other words,
colorectal adenomas are well-established precursor
lesions for colorectal cancer. Then, the value of
individual bile acids as a potential risk marker for
colorectal cancer can be further evaluated by
study of FBA profiles in patients carrying colorec-
tal adenoma. For bile acid metabolism, many
studies reported that patients with colorectal
adenoma also had an increased proportion of
DCA in their feces.
5,9 However, these studies have
been limited by small sample size. A meta-an-
alysis may provide a more precise understanding
of the true effect. Here, we performed a meta-
analysis of all eligible studies in order to address
the relationship between FBAs and colorectal
cancer or adenoma.
MATERIALS AND METHODS
Data sources and searches
Electronic databases (Pubmed, Embase, Cochrane
Controlled Trials Register, Science Citation Index,
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and Chinese Biomedical Database) were searched
up to March 2007 for all observational studies that
examined the relationship between bile acids and
colorectal cancer or adenoma. For the search, we
used both medical subject headings, textwords,
and their abbreviations: "bile acid", "cholic acid",
"chenodeoxycholic acid", "deoxycholic acid",
"lithocholic acid" and "ursodeoxycholic acid" in
combination with "colon cancer", "colonic cancer",
"rectal cancer", "colorectal cancer", "adenoma", and
"adenomatous polyps". Both literature searches
were limited to "human" and "English language",
except for Chinese in the Chinese Biomedical
Database. We also performed a manual search of
references cited by the original published studies
and relevant review articles. Authors of some
identified trials were asked whether they knew of
additional studies including unpublished ones.
The contents of abstracts or full-text manuscripts
identified through the literature search were
reviewed independently by 2 investigators (Tong
JL and Shen J) in duplicate to determine whether
they met eligibility criteria for inclusion. When
discrepancies between investigators occurred for
inclusion or exclusion, a third investigator (Ran
ZH) was involved to conduct additional evalua-
tion of the study and discrepancies were resolved
in conference.
Inclusion and exclusion criteria
For inclusion in the meta-analysis on the mean
concentrations of bile acids and colorectal cancer,
studies had to have an analytical design (case-
control, cohort, or cross-sectional) and examine
the relationship between bile acid concentrations
and colorectal cancer or adenoma. Studies were
included only if they were published as full-
length articles or letters in peer-reviewed journals.
All studies were required to have extractable data.
Data expressed as medians were not included in
the meta-analysis. For total or individual bile
acids, data reporting concentrations of bile acids
in fecal water were also not included. For
duplicate publications, the smaller dataset was
excluded. In all searches, we contacted the authors
to obtain the required information when relevant
information was not reported or there was doubt
about duplicate publications.
Data extraction
All data were independently abstracted in
duplicate by 2 investigators (Tong JL and Shen J)
using a standardized data collection form.
Discrepancies were resolved by discussing with a
third investigator (Ran ZH). Study characteristics
recorded were as follows: first author’s name,
year and source of publication, country of origin;
inclusion, exclusion criteria, outcomes, number
enrolled, mean age in each group, percentage of
females, number of control case groups, mean
levels of total bile acids, CDCA, DCA, LCA, and
primary and secondary bile acids.
In the case of trials with more than 2 groups,
and dichotomous outcomes, both the number of
events and total number of patients would be
halved; for continuous outcomes, only the total
number of participants would be halved.
Statistical analysis
Some of the studies included in our meta-
analysis differed in the unit used for reporting
levels of total bile acids ( mol/g vs. mg/g). μ
Therefore, we converted all units to mg/g using
the conversion factor 1 mol/g μ = 0.385 mg/g for
total FBAs.
We calculated the WMD and 95% CI for all
variables. The inverse variance method was used
to weight the studies. A fixed-effects model
approach was used but in case of heterogeneity,
a random-effects model was used. We assessed
heterogeneity with I
2, which describes the percen-
tage of total variation across studies because of
heterogeneity rather than chance. Negative values
of I
2 are put equal to 0. I
2 lies between 0% (no
observed heterogeneity) and 100%. I
2 values of
50% and more indicate a substantial level of
heterogeneity. The heterogeneity between groups
(cancer and adenoma) was also calculated using
chi-squared test and significance was set at p <
0.10. For subanalysis, we calculated the WMD and
95% CI by geographical location (Europe, Asia,
North America, and other continents) and lesions
(cancer vs. adenoma). Publication bias was as-
sessed with funnel plot. Begg and Egger tests were
also performed. All analyses were performed with
the statistical package Stata (ver. 9, Stata Corp.,Jin Lu Tong, et al.
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College Station, TX, USA) using the "metan" and
"metabias" commands. For forest plots, the size of
the box for each study represents the weight of
the study in the meta-analysis. The lines around
the point estimate represent the 95% CI for the
individual studies. The diamonds represent
summary estimates from the meta-analysis; the
width of the diamond is the 95% CI.
RESULTS
Description of studies
The bibliographical search resulted in 941 hits.
Of these studies, only 19 investigated the relation-
ship between FBAs and colorectal cancer or
adenoma. In addition to this, 1 study was iden-
tified in the Chinese Biomedical Database. Finally,
20 studies including a total of 1,226 individuals
fulfilled our inclusion criteria. The flowchart of
reviews showed the detailed process of selection
(Fig. 1). Of the articles included, 18 were case-
control
1-3,10-24 and 2 cohort designed.
25,26 Among
the 20 studies, 7 were conducted primarily in the
United Kingdom, 4 in Japan, 2 in France, 2 in
Germany, 1 in the United States, 1 in Finland, 1
in Northern Ireland, 1 in Greece, and 1 in China.
Table 1 summarizes the characteristics of the 20
trials included in the review. Table 2 shows the
Q-statistics and I
2 statistics for the overall analyses
and compared the results of random effects to
fixed effects models.
Total bile acid
Nineteen studies reported extractable data
about the relationship between total FBAs and
cancer/adenoma of the large bowel. No associa-
tion was seen (WMD 0.61 mg/g freeze-dried feces;
95% CI: - 0.35 - 1.57) in a random effects model (p
< 0.01, 
2 test; I
2 = 86.0%). When those studies were
divided by lesion (cancer vs. adenoma) in order
to explain the heterogeneity existed, the
heterogeneity existed. In a random effects model,
patients with large bowel cancer had a non
significant higher concentration of total bile acids
(WMD 0.43 mg/g freeze-dried feces; 95% CI: - 0.83
- 1.69) (p < 0.1, 
2 test; I
2 = 88.5%) (Fig. 2). Under
fixed effects model, the fecal excretion of total bile
acids was significantly higher in patients with
adenoma than in controls (WMD 0.66 mg/g
freeze-dried feces; 95% CI: 0.08 - 1.24), but this dif-
ference was no longer significant when based on
random effects models (WMD 1.13 mg/g freeze-
dried feces; 95% CI: - 0.25 - 2.51).
Individual bile acid
CDCA
Five studies reported the relationship between
CDCA and cancer/adenoma of the large bowel.
No heterogeneity existed about CDCA (p > 0.1, 
2
test; I
2 = 33.7%). Significantly increased concentra-
tion of CDCA was seen by a fixed effects model
when all studies were pooled to assess the
relationship between CDCA and cancer/adenoma
of the large bowel (WMD 0.13 mg/g freeze-dried
feces; 95% CI: 0.01 - 0.25). The fecal excretion of
CDCA was significantly higher in patients with
large bowel cancer than in matched controls
(WMD 0.28 mg/g freeze-dried feces, 95% CI: 0.10
- 0.46) in a fixed effects model (Fig. 3), and also
with random effects models (WMD 0.28 mg/g
freeze-dried feces; 95% CI: 0.09 - 0.48). However, Fig. 1. Trial flow for selection relating studies.Fecal Bile Acids and Colorectal Cancer
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no differences existed between patients with
adenoma and controls (WMD 0.00 mg/g freeze-
dried feces; 95% CI: - 0.17 - 0.17) by a fixed/
random effects model.
DCA
All studies were pooled to assess the relationship
between fecal DCA and cancer/adenoma of the
large bowel. DCA excretion in patients with
cancer/adenoma was not significantly different
compared to corresponding controls (WMD 0.24
mg/g freeze-dried feces; 95% CI: - 0.43 - 0.91;
random effects model). DCA excretion in patients
with cancer was significantly different compared
to corresponding controls under fixed effects
models (WMD 0.33 mg/g freeze-dried feces; 95%
CI: 0.10 - 0.57) (Fig. 4), but the significance was lost
with random effects models (WMD 0.01 mg/g
freeze-dried feces; 95% CI: - 0.86 - 0.88). However,
statistical heterogeneity was present (p < 0.01, 
2
test; I
2 = 89.2%). DCA excretion in patients with
adenoma on admission was significantly higher
than in patients with corresponding controls under
fixed effects models (WMD 0.69 mg/g freeze-
dried feces; 95% CI: 0.18 - 1.20). There was no
heterogeneity existed (p > 0.01, 
2 test; I
2 = 56.1%).
Table 1. General Characteristics of Included Studies which Assessed the Relationship between Fecal Bile Acids and
Colorectal Cancer or Adenoma
Author-year Location
Subjects
(cases/noncases)
Participants
(cases/noncases)
Dietary habits Confounder
Liver
function
Time of no
antibiotics
Hill-1975
1 UK CRC/NGD 44/28 NR
Age sex height
BW religion
NR NR
Reddy-1977
5 USA CC/AP/HS 31/13/34 Mixed Western Age sex religion NR > 4 wks
Mudd-1980
9 NI CRC/HS CRA/HS 20/20 19/19 Mixed unstricted Age sex NR > 1 mo
Hikasa-1984
10 Japan CRC/HS 14/14 No control Age sex BW Normal > 2 wks
Makino-1984
11 Japan CC/AP/PU 10/25/10 Hospital NR NR NR
Owen-1986
12 England CRC/HS 34/36 NR NR Normal NR
Kaibara-1983
13 Japan CRC/HS 15/10 Normal NR Normal > 3 wks
Owen-1987
14 UK CRC/HS 17/20 Western Age sex Mixed NR
Murray-1980
15 UK CRC/HS 37/36 Normal Sex NR > 1 mo
Korpela-1988
16 Finland CRC/HS 9/10 Omnivore Age height BW NR > 6 mos
Meance-2003
17 France CRA/HS 19/20 NR+probiotics* NR NR > 2 mos
Owen-1992
18 UK CRA/HS 68/24 NR Age sex NR NR
Breuer-1986
19 Germany AP/HS 12/12 Normal Age sex BW NR > 4 wks
Haines-2000
20 UK CRC/HS 69/200 NR Sex NR NR
Hill-1987
21 UK CRC/UC 14/88 NR Age sex NR NR
Perogambros-1982
22 Greece CC/HS 10/10 Mixed western Age sex NR NR
Breuer-1985
23 Germany CC/HS 23/21 Normal Age sex BW Mixed > 4 wks
Tanida-1984
24 Japan AP/HS 13/13 NR Age sex BW Normal > 4 wks
Huang-2000
25 China CRC/HS 24/16 NR Age sex Normal > 2 wks
Boutron-Ruault-2005
26 France CRA/CRA-free 17/28 NR Age sex BW NR > 2 mos
CRC, colorectal cancer; HS, healthy subjects; BW, body weight; NI, Northern Ireland; CC, colon cancer; CRA, colorectal adenoma;
PU, peptic ulcer; NGD, non-gastrointestinal disease; AP, adenomatous polyps; NR, not reported.
*Containing a diet with probiotics.
Including patients with liver metastases.Jin Lu Tong, et al.
Yonsei Med J Vol. 49, No. 5, 2008
Lithocholic acid
LCA excretion in patients with cancer was
significantly higher than in patients with cor-
responding controls under fixed effects models
(WMD 0.30 mg/g freeze-dried feces; 95% CI: 0.07
- 0.52) (Fig. 5), and no significance exists between
patients with adenoma and patients with corres-
ponding controls. All studies were pooled to
assess the relationship between fecal LCA and
cancer/adenoma of the large bowel. LCA excre-
tion in patients with cancer/adenoma was
nonsignificantly higher than in patients with
corresponding controls (WMD 0.61 mg/g freeze-
dried feces; 95% CI: - 0.03 - 1.24) under random
effects model.
Sum of primary and secondary bile acids
Primary bile acids in patients with cancer/
adenoma were slightly higher than in patients
with matched controls, but little differences were
seen (WMD 0.20 mg/g freeze-dried feces; 95% CI:
- 0.10 - 0.51) (random effects model) (Fig. 6). For
secondary bile acids, no significance was seen
between patients with cancer and patients with
matched controls regardless of fixed and random
effects models (Fig. 7).
Sub-analysis / sensitivity analysis
For sub analysis, we calculated the WMD and
95% CI by geographical location. In Europe, there
Table 2. Comparing Summary Statistics Using Random and Fixed Effects Models
Outcome/subgroup I
2*(%) p value
Random effects, WMD
(95% CI)
Fixed effects,
WMD (95% CI)
Total bile acid 86.0 < 0.001 0.61 (- 0.35 to 1.57) 0.14 (- 0.19 to 0.47)
Cancer 88.5 < 0.001 0.43 (- 0.83 to 1.69) - 0.11 (- 0.51 to 0.29)
Adenoma 68.9 0.004 1.13 (- 0.25 to 2.51) 0.66 (0.08 to 1.24)
CDCA 33.7 0.159 0.16 (0.00 to 0.32) 0.13 (0.01 to 0.25)
Cancer 14.0 0.325 0.28 (0.09 to 0.48) 0.28 (0.10 to 0.46)
Adenoma 0.0 0.622 0.00 (- 0.17 to 0.17) 0.00 (- 0.17 to 0.17)
DCA 86.1 < 0.001 0.24 (- 0.43 to 0.91) 0.40 (0.18 to 0.61)
Cancer 89.2 < 0.001 0.01 (- 0.86 to 0.88) 0.33 (0.10 to 0.57)
Adenoma 56.1 0.078 0.77 (- 0.11 to 1.66) 0.69 (0.18 to 1.20)
LCA 87.6 < 0.001 0.61 (- 0.03 to 1.24) 0.32 (0.12 to 0.53)
Cancer 89.9 < 0.001 0.57 (- 0.22 to 1.36) 0.30 (0.07 to 0.52)
Adenoma 80.4 0.002 0.71 (- 0.49 to 1.90) 0.45 (- 0.03 to 0.93)
Primary bile acids 54.4 0.052 0.20 (- 0.10 to 0.51) 0.16 (- 0.02 to 0.34)
Cancer 67.5 0.026 0.31 (- 0.14 to 0.75) 0.19 (- 0.02 to 0.39)
Adenoma 34.2 0.218 0.07 (- 0.40 to 0.53) 0.09 (- 0.28 to 0.46)
Secondary bile acids 30.3 0.208 - 0.01 (- 0.83 to 0.81) - 0.03 (- 0.70 to 0.64)
Cancer 0.0 0.616 - 0.43 (- 1.19 to 0.32) - 0.43 (- 1.19 to 0.32)
Adenoma 0.0 0.579 1.45 (- 0.00 to 2.91) 1.45 (- 0.00 to 2.91)
WMD, weighted mean difference; CI, confidence interval; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; LCA, lithocholic
acid.
*I
2 statistics for heterogeneity.
p value for Q-statistics.Fecal Bile Acids and Colorectal Cancer
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Fig. 2. Summary estimates of the
WMD for total bile acids con-
centration in individuals with
colorectal cancer/adenoma vs.
matched controls under random
effects model. CI, confidence
interval; WMD, weighted mean
difference.
Fig. 3. Summary estimates of
the WMD for CDCA concen-
tration in individuals with
colorectal cancer/adenoma vs.
matched controls under fixed
effects model. CI, confidence
interval; WMD, weighted mean
difference; CDCA, chenodeoxy-
cholic acid.Jin Lu Tong, et al.
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Fig. 4. Summary estimates of
the WMD for DCA concentra-
tion in individuals with colorec-
tal cancer/adenoma vs. matched
controls under random effects
model. CI, confidence interval;
WMD, weighted mean differ-
ence; DCA, deoxycholic acid.
Fig. 5. Summary estimates of
the WMD for LCA concentra-
tion in individuals with colorec-
tal cancer/adenoma vs. matched
controls under random effects
model. CI, confidence interval;
WMD, weighted mean difference;
LCA, lithocholic acid.Fecal Bile Acids and Colorectal Cancer
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was no difference between patients with cancer/
adenoma and patients with matched controls.
However, total bile acids excretion in patients
with cancer/adenoma was slightly higher than in
patients with matched controls in Asia, although
no significance was seen. There was only 1 study
investigating the relationship in North America
that showed significantly higher level of total bile
acids in patients with cancer/adenoma compared
to matched controls. In the sensitivity analysis, we
excluded the studies conducted by Meance et al.,
17
which contained probiotics in the diet. The
Fig. 6. Summary estimates of the
WMD for primary bile acids
concentration in individuals with
colorectal cancer/adenoma vs.
matched controls under fixed
effects model. CI, confidence
interval; WMD, weighted mean
difference.
Fig. 7. Summary estimates of
the WMD for secondary bile acids
concentration in individuals with
colorectal cancer/adenoma vs.
matched controls under fixed
effects model. CI, confidence
interval; WMD, weighted mean
difference.Fig. 8. Begg's funnel plot with pseudo
95% confidence limits showing WMD in
total bile acids by standard error of
WMD. WMD, weighted mean difference.
Jin Lu Tong, et al.
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concentration of total bile acids had no significant
changes.
Publication bias
For total bile acids excretion, no evidence of
publication bias was observed as indicated by a
symmetric funnel plot and a non-significant Begg
test (p = 0.47) and Egger test (p = 0.23) (Fig. 8).
DISCUSSION
Colorectal cancer is the third most common
cancer in both men and women, and is the second
leading cause of cancer deaths.
27 Investigators
have identified several risk factors that increase a
person's chance of developing colorectal cancer,
such as age, diet, large intestinal polyps, family
history of colon cancer, medical conditions, lack of
exercise, obesity, diabetes, smoking, familial
adenomatous polyposis, Gardner's syndrome,
etc.
28 Among these risk factors, observational
evidence to relate fecal bile acids and risk of
colorectal cancer/adenoma is abundant, however,
these studies reported contradictory conclusions.
Therefore, we performed a meta-analysis of all
eligible studies in order to address the relationship
between FBAs and colorectal cancer or adenoma.
The time-related analysis also suggested that FBA
concentrations are not an important risk factor for
carcinoma unless they are greater than 9 mg/g of
feces.
21 The finding of this analysis suggests no
association between total FBAs and cancer/
adenoma of the large bowel, regardless of being
based on fixed (WMD 0.14 mg/g freeze-dried
feces; 95% CI: - 0.19 - 0.47) and random effects
models (WMD 0.61 mg/g freeze-dried feces; 95%
CI: - 0.35 - 1.57). However, there was significant
heterogeneity (p < 0.01, 
2 test; I
2 = 86.0%). Adjust-
ment for clinically relevant confounders in these
studies makes this possibility less likely but does
not completely eliminate it. Our meta-analysis also
showed that the fecal excretion of CDCA was
significantly higher in patients with cancer/
adenoma than in controls (WMD 0.13 mg/g
freeze-dried feces; 95% CI: 0.01 - 0.25), especially
for colorectal cancer (WMD 0.28 mg/g freeze-
dried feces; 95% CI: 0.10 - 0.46). However, no
differences existed between patients with adenoma
and controls (WMD 0.00 mg/g freeze-dried feces;
95% CI: - 0.17 - 0.17). In vivo, CDCA markedly
enhanced tumor growth and increased vasculari-
zation via the COX-2 pathway.
29
Animal model experiments indicate that DCA
and LCA act as colon tumor promoters of an
established large bowel animal carcinogen.
30,31 For
fecal excretion of DCA and LCA, significantly
increased concentrations of DCA and LCA were
seen under fixed effects models [(WMD 0.40 mg/
g freeze-dried feces; 95% CI: 0.18 - 0.61) and
(WMD 0.32 mg/g freeze-dried feces; 95% CI: 0.12
Standard error of WMDFecal Bile Acids and Colorectal Cancer
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- 0.53), respectively]. However, the significance
was lost with random effects models [(WMD 0.24
mg/g freeze-dried feces; 95% CI: - 0.43 - 0.91) and
(WMD 0.61 mg/g freeze-dried feces; 95% CI: - 0.03
- 1.24), respectively]. There was also significant
heterogeneity. For the sum of primary and
secondary bile acids, no significances were seen
although there was no heterogeneity. Secondary
bile acids have been found to be mutagenic and
promote tumor growth in animal models, and the
feces of populations with a low risk of colonic
cancer contain relatively low proportions of
secondary bile acids.
32 Furthermore, it has been
shown that the proportion of secondary bile acids,
namely LCA and DCA, is a far better marker for
colorectal cancer.
LCAs and DCAs are the product of 7 - α
dehydroxylation of CDCA and cholic acids. Cholic
acid is mainly derived from endogenous choles-
terol whereas CDCA is synthesized mainly from
dietary cholesterol.
33,34 Some studies demonstrated
that Americans who consume a mixed Western
diet are, a high risk population and excreted high
levels of bile acids compared to Japanese, Chinese,
and American Seventh-Day Adventists, who are
at low risk.
35,36 We purposed that diet patterns
have a definite influence upon bile acids meta-
bolism.
Furthermore, many studies also reported the
ratio of LCA/DCA, and suggested that the ratio
of LCA/DCA may be an important discriminant
marker for susceptibility to colorectal cancer.
37
The LCA/DCA ratio was significantly higher in
the colorectal cancer group compared to the
control group.
14 Another interesting feature has
emerged from some studies that relate the LCA/
DCA ratio to the excretion of total FBAs, LCA/
DCA×FBA index showing a positive correlation
with colorectal cancer.
12
Many factors may contribute to the discrepancy
in results of observational studies. Firstly, wide
variations in the excretion of bile acids in feces
have been reported between individuals and
from day-to-day within the same individual.
Variations in bile acid metabolism might mainly
be influenced by age, transmit time, hepatic
function, liver metastases, use of medication, gall
bladder function, and undergoing previous
cholecystectomy and bowel surgery. Secondly,
methodological aspects including selection of
subjects, period of feces collection, and chemical
analysis of either total feces are of great
influence. Thirdly, FBA profiles are complex
because of bacterial deconjugation, dehydroxyla-
tion, oxidoreduction, and desulphation of bile
acids in the intestine.
This meta-analysis has several strengths and
limitations. Although funnel plot and formal
testing did not indicate publication bias, bias
cannot definitely be ruled out because of the
small number of studies and the low power of
any test to detect publication bias. There was
evidence of heterogeneity concerning the
outcomes of total bile acids, DCA, and LCA.
Adjustment for clinically relevant confounders in
these studies makes this possibility less likely but
does not completely eliminate it. One limitation
of our study is the lack of data from multiple
large trials. Furthermore, to some extent, the
techniques used for FBA determination, which
represent little advance since their development
in the mid 1960s, can be criticized for lacking in
specificity and being incapable of detecting trace
quantities of the types of compounds proposed as
carcinogens or cocarcinogens. Furthermore, the
definition of the sum of secondary bile acids is
different; some studies included DCA and LCA
which others included DCA, LCA, and
ursodeoxycholic acid. Nevertheless, the detailed
composition of the sum of primary bile acids in
each study is consistent.
In conclusion, by showing differences between
the bile acid profiles of patients with colorectal
adenomas or carcinomas and matched controls,
we provided further support for the concept that
bile acids have a role to play in the development
of large bowel tumors. The present findings also
raise possibility that the biochemical analysis of
fecal CDCA might be useful in screening
populations for high and low risk in developing
carcinoma of the colon.
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